| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells.
|
J Clin Invest
|
2004
|
3.70
|
|
2
|
Nanoparticle-based targeted drug delivery.
|
Exp Mol Pathol
|
2009
|
2.62
|
|
3
|
CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion.
|
Lab Invest
|
2004
|
2.01
|
|
4
|
Very small embryonic-like stem cells are present in adult murine organs: ImageStream-based morphological analysis and distribution studies.
|
Cytometry A
|
2008
|
1.93
|
|
5
|
Inhibition of IFN-gamma-inducible protein-10 abrogates colitis in IL-10-/- mice.
|
J Immunol
|
2003
|
1.39
|
|
6
|
CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication.
|
Endocr Metab Immune Disord Drug Targets
|
2007
|
1.33
|
|
7
|
Expression and functional role of CCR9 in prostate cancer cell migration and invasion.
|
Clin Cancer Res
|
2004
|
1.29
|
|
8
|
Morphological characterization of very small embryonic-like stem cells (VSELs) by ImageStream system analysis.
|
J Cell Mol Med
|
2007
|
1.26
|
|
9
|
IFN-gamma-inducible chemokines enhance adaptive immunity and colitis.
|
J Interferon Cytokine Res
|
2003
|
1.21
|
|
10
|
The ImageStream System: a key step to a new era in imaging.
|
Folia Histochem Cytobiol
|
2007
|
1.15
|
|
11
|
CXCL10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in IL-10(-/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition.
|
J Interferon Cytokine Res
|
2008
|
1.11
|
|
12
|
Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion.
|
Cancer Lett
|
2009
|
1.07
|
|
13
|
Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines.
|
Int J Cancer
|
2009
|
1.05
|
|
14
|
Past, present, and future technologies for oral delivery of therapeutic proteins.
|
J Pharm Sci
|
2008
|
1.05
|
|
15
|
Proteomic identification and functional characterization of a novel ARF6 GTPase-activating protein, ACAP4.
|
Mol Cell Proteomics
|
2006
|
1.05
|
|
16
|
Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk.
|
Prostate
|
2010
|
1.02
|
|
17
|
Host inflammatory response and development of complications of Chlamydia trachomatis genital infection in CCR5-deficient mice and subfertile women with the CCR5delta32 gene deletion.
|
J Microbiol Immunol Infect
|
2005
|
1.01
|
|
18
|
CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion.
|
Int J Oncol
|
2011
|
1.01
|
|
19
|
Differential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of pneumococcal carriage.
|
Infect Immun
|
2005
|
1.00
|
|
20
|
CCL5 modulates pneumococcal immunity and carriage.
|
J Immunol
|
2006
|
0.96
|
|
21
|
CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion.
|
World J Surg Oncol
|
2010
|
0.95
|
|
22
|
Chemokines: key players in cancer progression and metastasis.
|
Front Biosci (Schol Ed)
|
2011
|
0.94
|
|
23
|
Plasmodium yoelii 17XL infection up-regulates RANTES, CCR1, CCR3 and CCR5 expression, and induces ultrastructural changes in the cerebellum.
|
Malar J
|
2005
|
0.93
|
|
24
|
CXCL10+ T cells and NK cells assist in the recruitment and activation of CXCR3+ and CXCL11+ leukocytes during Mycobacteria-enhanced colitis.
|
BMC Immunol
|
2008
|
0.92
|
|
25
|
Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer.
|
Int J Oncol
|
2011
|
0.92
|
|
26
|
PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells.
|
Mol Cancer
|
2010
|
0.91
|
|
27
|
CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion.
|
World J Surg Oncol
|
2011
|
0.91
|
|
28
|
CCL5 regulation of mucosal chlamydial immunity and infection.
|
BMC Microbiol
|
2008
|
0.86
|
|
29
|
CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion.
|
J Ovarian Res
|
2010
|
0.86
|
|
30
|
Helper T cell epitope-mapping reveals MHC-peptide binding affinities that correlate with T helper cell responses to pneumococcal surface protein A.
|
PLoS One
|
2010
|
0.85
|
|
31
|
Influence of Mycobacterium avium subsp. paratuberculosis on colitis development and specific immune responses during disease.
|
Infect Immun
|
2007
|
0.85
|
|
32
|
Differential G protein subunit expression by prostate cancer cells and their interaction with CXCR5.
|
Mol Cancer
|
2013
|
0.85
|
|
33
|
Effects of HIV-1 Nef, a cytotoxic viral protein, on the growth of primary colorectal cancer.
|
Cancer Biol Ther
|
2005
|
0.83
|
|
34
|
Cigarette smoke condensate-induced oxidative DNA damage and its removal in human cervical cancer cells.
|
Int J Oncol
|
2011
|
0.82
|
|
35
|
Antibody Microarray Analysis of Signaling Networks Regulated by Cxcl13 and Cxcr5 in Prostate Cancer.
|
J Proteomics Bioinform
|
2012
|
0.82
|
|
36
|
CXCR4-gp120-IIIB interactions induce caspase-mediated apoptosis of prostate cancer cells and inhibit tumor growth.
|
Mol Cancer Ther
|
2009
|
0.82
|
|
37
|
Viral macrophage-inflammatory protein-II: a viral chemokine that differentially affects adaptive mucosal immunity compared with its mammalian counterparts.
|
J Immunol
|
2004
|
0.79
|
|
38
|
CCL5-independent helper T lymphocyte responses to immuno-dominant pneumococcal surface protein A epitopes.
|
Vaccine
|
2011
|
0.78
|
|
39
|
Granulocyte chemotactic protein-2 mediates adaptive immunity in part through IL-8Rbeta interactions.
|
J Leukoc Biol
|
2004
|
0.78
|
|
40
|
Increased expression of chemokines in the skin of chronic proliferative dermatitis mutant mice.
|
Exp Dermatol
|
2005
|
0.76
|
|
41
|
Prediction and characterization of helper T-cell epitopes from pneumococcal surface adhesin A.
|
Immunology
|
2014
|
0.75
|